A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors.

Trial Profile

A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications CNS cancer; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 12 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 May 2010 Results will be presented as the Americal Society of Clinical Oncology Annual Meeting 2010, according to an Ariad Pharmaceuticals media release.
    • 19 Mar 2010 Planned end date changed from 1 Jun 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top